Photo: REUTERS/Hollie Adams/File Photo Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis hasn't changed. Novo Nordisk is still a dominant player in a growing industry, ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish ...

The lawsuits follow an announcement by Novo Nordisk that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers’ sales and “deceptive” marketing of the ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

Shares in Denmark's pharmaceutical giant Novo Nordisk (NYSE: NVO) were lower by 4% as of 11 a.m. ET today. The move comes as the fallout from the sudden termination of its partnership with ...